Navigation Links
Inflammatory cues modulate goblet cell products important for intestinal barrier function
Date:12/2/2011

In a paper published in the December 2011 issue of Experimental Biology and Medicine, a team of scientists at the University of Illinois, Urbana-Champaign led by Rex Gaskins, PhD have demonstrated that both microbial and host inflammatory factors modulate sulfomucin production in a human cell line, LS174T, that models intestinal goblet cells.

Sulfomucins, one of two primary types of acidomucins secreted by intestinal goblet cells, provide crucial protection to the intestinal mucosa. Therefore, it is not surprising that a loss of intestinal sulfomucins is associated with both inflammatory bowel disease (IBD) and colorectal cancer. However, the extent to which pathways involved in sulfomucin production are responsive to signals emanating directly from intestinal microbes or cues originating from host inflammatory cells is not known.

The research team at the University of Illinois compared the effects of bacterial flagellin to the mucogenic cytokine IL-13, and the proinflammatory cytokine TNF on expression of genes encoding the Golgi sulfotransferases involved in addition of sulfate groups to mucin precursors and sulfomucin production. They observed high induction of carbohydrate (N-acetyl-glucosamine 6-O) sulfotransferase 5 (CHST5) as early as 12 h after treatment with IL-13. Flagellin, IL-13 and TNF all, on the other hand, induced expression of the other sulfotransferase galactose-3-O-sulfotransferase 2 (GAL3ST2). The observed induction of sulfotransferases was consistent with increased sulfomucin production by LS174T cells in response to IL-13 and flagellin, indicating that sulfotransferases and sulfomucin synthesis can be differentially modulated by particular inflammatory signals.

Galactose-3-O-sulfotransferase 2 is thought to be the sulfotransferase responsible for sulfate addition to the C-3 position of galactose in human colonic mucins. On the other hand, CHST5 is the most likely candidate for sulfation of the C-6 position of N-acetylglucosamine. GAL3ST2 expression was enhanced in LS174T cells following treatment with flagellin, IL-13 and TNF, indicating that increased mucin sulfation at the C-3 position of galactose might be a common response to inflammatory stimuli.

Although cautious to point out that the present study derives from a well-differentiated, but transformed goblet cell line, Professor Gaskins said that "the data implicate biosynthesis of sulfomucins as a potential therapeutic target for the restoration of barrier function in chronic intestinal inflammatory disorders. Recent studies provide strong evidence that both ulcerative colitis (UC) and Crohn's disease (CD), the two primary types of IBD, result from multifactorial interactions among genetic, environmental and immunological factors that lead to a dysregulation of the innate immune response to the intestinal microbiota in genetically predisposed individuals."

The results with TNF are of particular interest because of its association with IBD and the alterations in mucin sulfation seen with active IBD. As IBD is characterized by dysregulated immune responsiveness, it may be that individuals with IBD fail to respond appropriately to TNF and, hence, fail to increase the production of sulfomucins. However, much additional work will be needed to better understand the mechanisms by which flagellin, IL-13, and TNF enhance expression of specific sulfotransferases and sulfomucin production.

Dr. Steve Goodman, Editor-in-Chief of Experimental Biology and Medicine said "Crohn's disease and ulcerative colitis (UC), the two primary types of inflammatory bowel disease (IBD), afflict 0.1-0.5% of individuals in Western countries with approximately 1 million Americans suffering from the disease at a cost of over $2 billion. This impressive study by Gaskins and colleagues identifies sulfomucins as potential targets for future therapies for chronic intestinal inflammatory disorders".
'/>"/>

Contact: Dr. H. Rex Gaskins
hgaskins@illinois.edu
217-444-3165
Society for Experimental Biology and Medicine
Source:Eurekalert

Related biology news :

1. Signaling pathway linked to inflammatory breast cancer may drive disease metastasis
2. Cleveland Clinic study discovers new targets for treating inflammatory, autoimmune diseases
3. A novel mechanism that regulates pro-inflammatory cells is identified
4. Research links 29 genome regions with common form of inflammatory bowel disease
5. Scientists find the master switch for key immune cells in inflammatory diseases
6. Immune system changes linked to inflammatory bowel disease revealed
7. Discovery of an anti-inflammatory substance
8. Researchers develop oral delivery system to treat inflammatory bowel diseases
9. Interfering with a double-edged sword: novel anti-inflammatory functions for interferons
10. Insulin may reduce several inflammatory factors induced by bacterial infection
11. Low bone mineral density common in children and teenagers with inflammatory bowel disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/25/2017)... The Elements of Enterprise Information Security ... of a comprehensive set of business processes and ... identities and providing a secured and documented access ... number of programs opted by enterprises to maintain ... processes and changing policies. However, there are some ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 According to ... Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor market is ... from 2016 to 2022. In 2015, Asia-Pacific dominated the ... public and private sectors. Continue Reading ... ...
(Date:1/12/2017)... SAN DIEGO , Jan. 12, 2017  Trovagene, ... circulating tumor DNA (ctDNA) technologies, today announced that it ... Europe and the Middle ... biopsy tests.  This milestone marks the first wave of ... tests for urine and blood samples. The ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... Dr. Kingsley Chin, professor and Harvard trained surgeon, completed the procedure on Monday, ... on a 55-year-old practicing female physician suffering from degenerative disc disease with radiculomyelopathy, ...
(Date:2/16/2017)... , ... February 16, 2017 ... ... Molecular Research Inc. has further extended its industry leading Biochemistry Services specifically ... offers state-of-the-art cGMP techniques and methods for the biochemical and biosimilar ...
(Date:2/15/2017)... , Feb. 15, 2017  NASA provider SpaceX is ... to the  International Space Station  no earlier than 10:01 ... launch will begin at 8:30 a.m. on NASA Television ... Dragon spacecraft will lift off on the company,s ... Kennedy Space Center in ...
Breaking Biology Technology: